| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 25, 2022Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the...
-
Sep 13, 2022
Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of...
-
Sep 1, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:...
Aug 18, 2022Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance...
Aug 9, 2022Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomas On track to initiate our Phase 2 clinical trial for the potential...